Legend Biotech to Host Investor Event During the 66th American Society of Hematology (ASH) Annual Meeting and Exposition
Legend Biotech (NASDAQ: LEGN) has announced an upcoming investor event during the 66th ASH Annual Meeting in San Diego. The live webcast is scheduled for December 8, 2024, at 8:00 p.m. PT (11:00 p.m. ET). CEO Ying Huang and CMO Mythili Koneru will host expert clinicians to discuss updates from the CARTITUDE development program. Investors can access the webcast through a provided weblink or the company's website under Events and Presentation section.
Legend Biotech (NASDAQ: LEGN) ha annunciato un prossimo evento per investitori durante il 66° Congresso Annuale ASH a San Diego. La trasmissione in diretta è programmata per l'8 dicembre 2024, alle 20:00 PT (23:00 ET). Il CEO Ying Huang e il CMO Mythili Koneru ospiteranno clinici esperti per discutere gli aggiornamenti del programma di sviluppo CARTITUDE. Gli investitori possono accedere alla trasmissione tramite un link fornito o attraverso il sito web dell'azienda nella sezione Eventi e Presentazioni.
Legend Biotech (NASDAQ: LEGN) ha anunciado un próximo evento para inversores durante el 66º Congreso Anual de ASH en San Diego. La transmisión en vivo está programada para el 8 de diciembre de 2024, a las 8:00 p.m. PT (11:00 p.m. ET). El CEO Ying Huang y la CMO Mythili Koneru recibirán a clínicos expertos para discutir actualizaciones sobre el programa de desarrollo CARTITUDE. Los inversores pueden acceder a la transmisión a través de un enlace proporcionado o en el sitio web de la empresa en la sección de Eventos y Presentaciones.
레전드 바이오텍 (NASDAQ: LEGN)는 샌디에고에서 열리는 제66회 ASH 연례 회의 중에 다가오는 투자자 이벤트를 발표했습니다. 생중계는 2024년 12월 8일 오후 8시 PT(오후 11시 ET)로 예정되어 있습니다. CEO 잉 황과 CMO 미틸리 코네루는 전문가 클리니션을 초청하여 CARTITUDE 개발 프로그램에 대한 업데이트를 논의할 것입니다. 투자자들은 제공된 웹 링크를 통해 또는 회사 웹사이트의 이벤트 및 프레젠테이션 섹션을 통해 생중계에 접속할 수 있습니다.
Legend Biotech (NASDAQ: LEGN) a annoncé un prochain événement pour les investisseurs lors de la 66e Réunion Annuelle de l'ASH à San Diego. La diffusion en direct est prévue pour le 8 décembre 2024, à 20h00 PT (23h00 ET). Le PDG Ying Huang et la CMO Mythili Koneru accueilleront des cliniciens experts pour discuter des mises à jour du programme de développement CARTITUDE. Les investisseurs peuvent accéder à la diffusion via un lien fourni ou sur le site web de l’entreprise dans la section Événements et Présentations.
Legend Biotech (NASDAQ: LEGN) hat eine kommende Investorenveranstaltung während des 66. ASH Jahrestreffens in San Diego angekündigt. Die Live-Übertragung ist für den 8. Dezember 2024, um 20:00 Uhr PT (23:00 Uhr ET) geplant. CEO Ying Huang und CMO Mythili Koneru werden Experten aus der Klinik einladen, um Updates zum CARTITUDE-Entwicklungsprogramm zu besprechen. Investoren können über den bereitgestellten Weblink oder über die Unternehmenswebsite im Abschnitt Veranstaltungen und Präsentationen auf die Übertragung zugreifen.
- None.
- None.
SOMERSET, N.J., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a live webcast event for investors on Sunday, December 8, 2024, at 8:00 p.m. PT (11:00 p.m. ET) during the 66th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, CA.
During the webcast, Ying Huang, Ph.D., Chief Executive Officer, and Mythili Koneru, M.D., Ph.D., Chief Medical Officer, will host expert clinicians as they review the latest updates from the CARTITUDE development program.
Investors and other interested parties may join the live webcast through this weblink or by visiting Legend Biotech’s website under Events and Presentation.
About Legend Biotech
Legend Biotech is a global biotechnology company dedicated to treating, and one day curing, life-threatening diseases. Headquartered in Somerset, New Jersey, we are developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogeneic chimeric antigen receptor T-cell, gamma-delta T cell and natural killer (NK) cell-based immunotherapy. From our three R&D sites around the world, we apply these innovative technologies to pursue the discovery of cutting-edge therapeutics for patients worldwide.
Learn more at www.legendbiotech.com and follow us on X (formerly Twitter) and LinkedIn.
INVESTOR CONTACT:
Jessie Yeung
Tel: (732) 956-8271
jessie.yeung@legendbiotech.com
PRESS CONTACT:
Mary Ann Ondish
Tel: (914) 552-4625
media@legendbiotech.com
FAQ
When is Legend Biotech (LEGN) hosting its investor event at ASH 2024?
What will be discussed at Legend Biotech's (LEGN) ASH 2024 investor event?
How can investors access Legend Biotech's (LEGN) ASH 2024 presentation?
